Bauerlein Alison 4

What Happened

• Alison Bauerlein, Chief Operating Officer of Sight Sciences, was granted 127,512 restricted stock units (RSUs) on February 3, 2026. The filing reports an acquisition price of $0.00 (award) but notes the grant was sized as $825,000 divided by the closing stock price on the grant date (≈$825,000 total grant value).
• The RSUs vest in 16 equal quarterly installments beginning March 31, 2026 and continuing through December 31, 2029, subject to continued service. This is an equity award (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-02-03; Grant type: RSU award (Code A); Amount: 127,512 RSUs; Reported acquisition price: $0.00.
• Grant value: Determined as $825,000 divided by the closing price on the grant date (per filing footnote).
• Shares owned after transaction: filing shows 135,620 shares of common stock owned outright and 591,875 shares subject to unvested RSUs (per footnote).
• Vesting schedule: 16 equal quarterly installments from 3/31/2026 through 12/31/2029, contingent on continued service.
• Filing timeliness: Reported on Form 4 filed 2026-02-05 for a 2026-02-03 grant — appears to be filed within the standard 2-business-day window for Section 16 insiders.

Context

• RSUs are a contingent right to receive shares upon vesting; they are not immediate purchases and do not represent an immediate market buy or sell decision. Vesting over multiple quarters ties the award to continued employment and potential future dilution when settled.
• The filing lists acquisition price as $0.00 because this is an award; the grant’s economic value is described in the footnote ($825,000 basis). Tax withholding or settlement mechanics are not detailed in the filing.